AIM AIM ImmunoTech

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022. In addition to management’s presentations, the Company is proud to announce its sponsorship of the event.

Presentation Details:

Title: Rintatolimod (Ampligen®): An Investigational Immunomodulatory Agent Targeted at Cancers of High Unmet Need

Author: Christopher McAleer, Ph.D.

Date: Saturday, September 10

Title: The Mechanism of PAMP Restricted Rintatolimod in Limiting Systemic Inflammatory Responses

Author: William M. Mitchell, M.D., Ph.D.

Date: Saturday, September 10

Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.

For more information about the conference, visit: .

The presentations will be available on the AIM once presented at the conference.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.



For more information, please visit and connect with the Company on , , and .



Investor Relations Contact
JTC Team, LLC
Jenene Thomas 
833-475-8247
EN
06/09/2022

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provi...

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or...

August 15, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Present at the Webull Financial Corporate Connect We...

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Live video webcast on Wednesday, August 20th at 2:40 PM ET   OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:40 PM ET Presenter: Registration Link: About Webull Financial Webull Financial is a leading online brokerage platform committed t...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presenta...

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) There will be presentations on the latest positive progress from AIM’s clinical program in pancreatic cancer, the positive therapeutic effects of AIM’s drug Ampligen on multiple cancer types, and Ampligen’s mechanism of action in oncology Discussion will also feature an abstract and oral presentation on Ampligen’s positive impact on endometriosis, a known precursor to ovarian cancer OCALA, Fla...

August 6, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Drivin...

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) toda...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of $4.00 per share (or $3.999 per pre-funded warrant) and accompanying warran...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch